CIRCULAR

Please find enclosed herewith guidelines with regard to management of co-infection of COVID-19 with other seasonal epidemic prone diseases as received from the Government of India Ministry of Health & Family Welfare Directorate General of Health Services (EMR Division), for taking further necessary action in the matter accordingly.

Endst. No. Aa as above
Copy for information and necessary action to:

1. The Secretary (Health) to the Government of Himachal Pradesh.
2. The Director Health Services, Himachal Pradesh.
3. The Director Medical Education & Research, Himachal Pradesh.
4. The Deputy Commissioners, Himachal Pradesh.
5. The Chief Medical Officers in Himachal Pradesh.
6. All the Medical Superintendents, in Himachal Pradesh
7. All the Nodal Officers DCCC/DCHC/DCH in Himachal Pradesh.
8. All the District Surveillance Officers in Himachal Pradesh.
Guidelines for management of co-infection of COVID-19 with other seasonal epidemic prone diseases

1. Background

Almost all States/UTs of the country are affected by COVID-19. Given the seasonal pattern of epidemic prone diseases observed every year in our country, it diseases like Dengue, Malaria, Seasonal Influenza, Leptospirosis, Chikungunya, Enteric fever, etc. can not only present as a diagnostic dilemma but may co-exist in COVID cases. This poses challenges in clinical and laboratory diagnosis of COVID-, and have a bearing on clinical management and patient outcomes.

2. Scope

The scope of this document is to provide clear guidelines on prevention and treatment of co-infections of COVID with diseases like Dengue, Malaria, Seasonal Influenza (H1N1), Leptospirosis, Chikungunya etc.

3. Clinical features

As per the World Health Organization (WHO) case definition, a COVID case may present with:

- Acute onset of fever AND cough;
- OR
- Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia/nausea/vomiting, diarrhoea, altered mental status.

This case definition, although sensitive, is not very specific. Seasonal epidemic prone diseases, as cited in the foregoing paragraphs may all present as febrile illness, with symptoms that mimic COVID-19. If there is a co-infection, then apart from the febrile illness there may be constellation of signs and symptoms that may lead to difficulty in diagnosis. A comparative analysis of disease onset, symptoms, signs, warning signs, complications and diagnosis is given at Annexure.

4. Approach to diagnosis of suspected co-infection

A high index of suspicion must be maintained for epidemic prone diseases (e.g. Dengue, Malaria, Chikungunya, Seasonal influenza, Leptospirosis) prevalent in a particular geographic region during monsoon and post-monsoon seasons. Bacterial co-infections must also be suspected in moderate or severe cases of COVID-19 not responding to treatment.

- **Malaria/Dengue**: It must be borne in mind that malaria/dengue can coexist with other infections, and thus confirmation of malaria/dengue infection does not rule out the possibility of the patient not suffering from COVID-19. Similarly, a high index of suspicion of malaria/dengue must be there when a fever case is diagnosed as COVID-19, particularly during the rainy and post rainy season in areas endemic for these diseases.
• **Seasonal Influenza:** Both COVID-19 and Seasonal Influenza present as Influenza Like Illness (ILI)/SARI, hence all ILI/SARI cases in areas reporting COVID-19 cases must be evaluated and tested for both COVID-19 and Seasonal Influenza, if both viruses are circulating in population under consideration.

• **Chikungunya:** Chikungunya presents with acute onset of moderate to high grade continuous fever and malaise followed by rash, myalgia and arthralgia. Respiratory failure may ensue in late stages. Co-infection with COVID-19 may be suspected in Chikungunya endemic areas, in the months of monsoon.

• **Leptospirosis:** Leptospirosis apart from it presenting as febrile illness, has also the tendency to manifest as acute respiratory illness, leading to respiratory distress and shock. In areas where Leptospirosis is known to cause outbreaks during monsoon/ post monsoon, the possibility of co-infection should be considered.

• **Scrub Typhus:** Scrub typhus is known to be prevalent in foothills of Himalayas viz Jammu & Kashmir, Himachal Pradesh, Sikkim, Manipur, Nagaland, Meghalaya, etc. However, in recent past, scrub typhus outbreaks have also been reported from Delhi, Haryana, Rajasthan, Maharashtra, Uttarakhand, Chhattisgarh, Tamil Nadu and Kerala. The clinical picture consists of sudden high-grade fever, severe headache, apathy, myalgia and generalized lymphadenopathy. A maculopapular rash may appear first on the trunk and then on the extremities and blanches within a few days. The patients may develop complications that include interstitial pneumonia (30 to 65% of cases), meningoencephalitis and myocarditis. Scrub typhus infection may co-exist with COVID-19.

• **Bacterial infections:** Few patients with COVID-19 experience a secondary bacterial infection. In such cases, empiric antibiotic therapy as per local antibiogram needs to be considered.

Despite the possibility of above mentioned co-infections, in present times of the pandemic, approach to diagnosis for COVID-19 essentially remains the same. Testing protocol as per MoHFW/ICMR guidelines will be followed. However, in addition, further tests for a likely co-infection will also be undertaken, whenever suspected.

5. Diagnostics

While each of these infections are antigenically distinct with specific serological responses, yet in the eventuality of co-infections, cross-reactions (resulting in false-positive /false negative results) cannot be totally ruled out, especially if the testing kits used are not having requisite sensitivity and specificity. Hence the tests recommended by ICMR (for COVID-19) and that recommended by the concerned programme divisions (NVBDCP for vector borne diseases [Malaria, Dengue, Chikungunya]) and NCDC (Seasonal Influenza, Leptospirosis, Scrub Typhus) needs to be followed. Availability of rapid diagnostic kits for malaria, dengue, scrub typhus should be ensured in such COVID treatment facilities.

The table below summarizes the various (confirmatory) test to be undertaken for possible co-infections.
Laboratory Testing: Co-infection of COVID-19 with other seasonal epidemic prone diseases

<table>
<thead>
<tr>
<th>Diseases</th>
<th>Tests</th>
<th>Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue</td>
<td>NS1 antigen ELISA or RT PCR: For &lt; 5 days of illness</td>
<td>Blood/Serum</td>
</tr>
<tr>
<td></td>
<td>IgM capture ELISA (MAC-ELISA): For &gt;5 days of illness</td>
<td></td>
</tr>
<tr>
<td>Chikungunya</td>
<td>Early disease: RT PCR</td>
<td>Blood/Serum</td>
</tr>
<tr>
<td></td>
<td>After first week of illness: IgM capture ELISA</td>
<td></td>
</tr>
<tr>
<td>H1N1</td>
<td>Acute phase: RT PCR</td>
<td>Naso/Oropharyngeal swab</td>
</tr>
<tr>
<td>COVID 19</td>
<td>Acute phase: RT PCR</td>
<td>Nasopharyngeal/ Oropharyngeal swab</td>
</tr>
<tr>
<td>Malaria</td>
<td>RDT (bi-valent both Pf/Pv detection)</td>
<td>Blood</td>
</tr>
<tr>
<td></td>
<td>Quality microscopy for slide positivity confirmation</td>
<td></td>
</tr>
<tr>
<td>Leptospirosis</td>
<td>In endemic areas: IgM ELISA and MAT tests</td>
<td>Blood</td>
</tr>
<tr>
<td></td>
<td>Non-endemic areas: IgM ELISA followed by MAT test for confirmation</td>
<td></td>
</tr>
<tr>
<td>Scrub Typhus</td>
<td>Detection of IgM antibodies by Weil-Felix Test (WFT)</td>
<td>Serum</td>
</tr>
<tr>
<td></td>
<td>Enzyme linked Immunosorbent assay (ELISA)</td>
<td></td>
</tr>
<tr>
<td>Bacterial co-infections</td>
<td>Gram stain and culture, Blood culture</td>
<td>Sputum/Bronchial aspirate/Blood</td>
</tr>
</tbody>
</table>

6. Case Management

Management of co-infection of COVID-19 with dengue, Influenza and bacterial co-infections may however be challenging and are dealt with in greater detail here.

6.1 Management of COVID-19 and Dengue co-infection

6.1.1 Pathogenesis

Dengue Fever and COVID-19 share many pathogenic and clinical features which might make it very difficult to differentiate the two infections (1). The phenomenon of ADE (Antibody Dependent Enhancement) has been described for both dengue virus as well as for SARS-CoV-2 virus resulting in escalation in degree of infection and number of complications. Both being RNA viruses they share certain common features in pathogenesis, eventually leading to subsequent cytokines and chemokine release and also affecting the integrity of the vascular endothelium leading to vasculopathy, coagulopathy and capillary leak. Various mechanisms can explain the signs and symptoms observed in co-infected patients but most will have the following, (i) Antibody-dependent enhancement (ADE), (ii) Cytokine Storm, (iii) Vasculopathy and (iv) Coagulopathy.

6.1.2 Clinical Features

The clinical features of both the infections are overlapping, both present as acute febrile illness of short duration and may have thrombocytopenia and shortness of breath, although respiratory
symptoms are more common in COVID-19 and bleeding manifestations more common in Dengue. Routine testing for both diseases shows leucopenia or normal leucocyte count. Decrease in platelet count which is a defining feature of dengue infection but can also be seen in significant number of covid cases. There are reports in literature, where dengue serology was positive initially and later on, it was found that cases were positive by RT-PCR for COVID-19 thereby suggesting that dengue serology can be falsely positive in COVID-19 patients. Therefore, there is a need to rely on more specific tests for each disease like throat swab RT-PCR for COVID-19 and ELISA based Dengue NS1 Antigen or serology test for dengue diagnosis. Serum sample for NS1 antigen within first 5 day of onset of fever were negative in above study suggesting that positive dengue serology was more likely to be false positive result and not co-infection. Hence, one needs to be careful while making diagnosis of co-infection.

There are now enough evidences to support that severe dengue is associated with cytokine storm and high levels of various circulating cytokine are associated with poor outcome in most cases. COVID-19 infects alveolar epithelial cells leading to pneumonia and ARDS, it also infects monocytes/macrophages leading to cytokine storm associated with multi organ failure and death. This cytokine storm seen in severe cases has led to increased use of steroids and other immunosuppressive therapy in moderate to severe cases.

Both COVID-19 and Dengue infection are accompanied by coagulopathy and vasculopathy with coagulopathy being predominant in formal leading to widespread use of Low Molecular Weight Heparin (LMWH). There have been numerous evidences to suggest the increased burden of thrombosis in COVID-19 based on which recommendations have been made for the use of LMWH in moderate to severe cases. But in the presence of Dengue co-infection which is usually accompanied by thrombocytopenia and increased risk of bleeding , the use of LMWH becomes a challenging issue. Similarly, because of increased capillary leak and increased third space fluid loss, fluid administration which forms the cornerstone in management of dengue might not be recommended with clarity as conservative fluid administration has been recommended for COVID-19 in absence of shock.

6.1.3 Clinical management consideration for Dengue and COVID-19 co-infection

Following are some general measures to followed in case of Dengue and COVID-19 co-infection:

- Co-infection should be ruled out when suspected with proper diagnostic method at the early stage to initiate proper specific management to reduce morbidity and mortality.

- Strengthening at the primary health care level is the key to manage dengue through early clinical diagnosis and recognition of warning signs for severity of Dengue (such as abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy or restlessness, liver enlargement >2 cm, and increase in haematocrit).

- Mild to moderate Dengue and COVID co-infected patient should be monitored closely preferably at hospital, as they may rapidly progress to severe stage therefore they should be referred to higher centre at the early stage by recognizing warning signs.

- At the same time, all secondary and tertiary level hospitals should be prepared to manage severe dengue and COVID cases.
These measures will help to prevent the progression of illness to severe dengue and deaths, which in turn will also help to reduce the number of patients that need to be referred to hospitals, thus avoiding saturation of these facilities as well as the intensive care units.

6.1.4 Specific therapeutic considerations

Points related with specific therapeutic options and their use in cases with co-infection:

- Fluid Therapy – Fluid therapy to be given in co-infection cases depends on hemodynamic status of patient and degree of severity. One may follow national guidelines for clinical management of dengue fever for most co-infection cases. It is only in the presence of SARI with COVID-19 that we need to be careful with aggressive fluid administration as it leads to worsening of oxygenation. Close clinical monitoring of fluid status is required in such cases. Aggressive fluid resuscitation is recommended for COVID-19 patients in shock for initial resuscitation.
- LMWH – LMWH is being used and has been included in the National guidelines for the management of moderate to severe covid-19 cases as it is associated with increased thrombosis. Once the platelet count decreases to less than 1 lakh we need to be very careful with the use of LMWH and it may be withheld based on clinical condition of the patient. Decision to administer LMWH and the dosage for the same should be based on close monitoring with D-dimer measurements. In any case of co-infection with active bleeding, LMWH needs to be stopped immediately.
- Use of Corticosteroids – Steroids specially Dexamethasone have recently been shown to be effective in severe covid-19 cases and have been recommended for the same. Dengue being a viral illness, it’s course won’t be affected much. Hence, use of steroids can be continued as per COVID-19 management guidelines.
- Tocilizumab – To be used as per national management guidelines for COVID-19 management.
- Antivirals – To be used as per COVID-19 management guidelines.
- Other supportive management to be continued as per the current guidelines.

6.2 Management of Seasonal influenza and COVID co-infection

Co-infection with SARS-CoV-2 and other respiratory viruses has been described in a number of studies. Most prominent among these are Respiratory Syncytial Virus, Enteroviruses and Influenza A virus. With the approaching winter season, the seasonal Influenza cases may show an upward trend, and there could be cases of co-infection with COVID-19.

6.2.1 Pathogenesis

COVID-19 and Influenza share many pathogenic feature. Both diseases involve the respiratory system, manifesting widely from ILI to SARI. Both diseases cause pneumonitis. The histopathological manifestation of Interstitial inflammation and diffuse alveolar damage and intra-alveolar edema followed by fibrin deposition, hyaline membrane, and leukocyte infiltration of the alveolar septa are seen in both COVID and Influenza. The radiological appearance is not of much help either as both diseases may have presence of opacities or consolidations.

Both being RNA viruses they share certain common features in pathogenesis, eventually leading to subsequent cytokine release and acute respiratory distress syndrome.

6.2.2 Diagnosis
Whenever suspected, especially in areas reporting seasonal Influenza cases, samples should also be sent and tested for SARS-CoV-2 and Influenza.

6.2.3 Clinical Features

The clinical features of both the infections are overlapping, both present as acute febrile illness of short duration and may have fever, cough and shortness of breath. Similarly, laboratory investigations are also not very helpful in differentiating between the two, both show leucopenia or normal leucocyte count. Co-infection should be ruled out when suspected with proper diagnostic method at the early stage to initiate proper specific management to reduce morbidity and mortality.

6.2.4 Specific therapeutic considerations

Points related with specific therapeutic options and their use in cases with co-infection:

- The specific treatment as provided in the clinical management protocol of COVID needs to be followed, as per severity of the disease.
- In addition to COVID management, for the treatment of influenza, Oseltamivir needs to be administered in the prescribed dosages.
- In case of an outbreak of Seasonal Influenza outbreak, Oseltamavir blanket therapy should be considered in all patients of COVID-19.
- Other supportive management to be continued as per the current guidelines.

6.3 Management of Bacterial co-infections with COVID

Evidence shows that small proportion of COVID-19 patients may have coinfection with bacteria. Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes. A recent systemic review on co-infections in people with COVID-19 has found that the commonly associated pathogens in such cases are Mycoplasma pneumoniae, Psuedomonas aeroginosa, Hemophilus influenzae, Klebsiella pneumoniae etc.

The occurrence of healthcare associated infections like hospital acquired pneumonia (particularly in ICU settings), urinary tract infection, skin/soft tissue infection, abdominal infections, etc.) need to be considered.

Antibiotics should not be prescribed routinely unless there is clinical suspicion of a bacterial infection. Consider empiric antibiotic therapy as per local antibiogram. For COVID-19 patients with severe disease, also collect blood cultures, ideally prior to initiation of antimicrobial therapy.

6.4 Management of Malaria and COVID-19 co-infection

6.4.1 Pathogenesis

Malaria is a potentially life-threatening parasitic disease caused by a protozoan having four types: Plasmodium vivax (P. vivax), Plasmodium falciparum (P. falciparum), Plasmodium malariae (P. malariae) and Plasmodium ovale (P. ovale). It is transmitted by the infective bite of Anopheles female mosquito. Man develops disease after 10 to 14 days of being bitten by an infective mosquito. Two types of parasites of human malaria, Plasmodium vivax (Pv), P. falciparum (Pf), are commonly
reported from India. Inside the human host, the parasite undergoes a series of changes as part of its complex life cycle. The parasite completes life cycle in liver cells (pre-erythrocytic schizogony) and red blood cells (erythrocytic schizogony).

Infection with P. falciparum is the deadliest form of malaria.

### 6.4.2 Diagnosis

Diagnosis of malaria may be made by the use of RDT (bivalent) or microscopic examination of the blood smear. Early diagnosis and prompt initiation of treatment, as per national guidelines, is the key in preventing the progression of uncomplicated malaria to severe forms which can be fatal. In the current scenario, in endemic areas, all fever cases should be tested for malaria using RDT kits.

### 6.4.3 Clinical Features

Typically, malaria produces fever, headache, vomiting and other flu-like symptoms. The parasite infects and destroys red blood cells resulting in easy fatigue ability due to anemia, fits/convulsions and loss of consciousness. Parasites are carried by blood to the brain (cerebral malaria) and to other vital organs. Malaria in pregnancy poses a substantial risk to the mother, the fetus and the newborn infant. Pregnant women are less capable of coping with and clearing malaria infections, adversely affecting the unborn fetus.

### 6.4.4 Specific therapeutic considerations

Prompt malaria case management is very important for preventing serious cases and death due to malaria.

Plasmodium vivax (Pv) cases should be treated with Chloroquine for three days (25 mg/kg body weight divided over three days i.e. 10 mg/kg on day 1, 10 mg/kg on day 2 and 5 mg/kg on day 3) and Primaquine (0.25 mg/kg body weight daily for 14 days). Primaquine is used to prevent relapse but is contraindicated in pregnant women, infants and individuals with G6PD deficiency.

Plasmodium falciparum (Pf) cases should be treated with ACT (Artesunate 3 days + Sulphadoxine-Pyrimethamine 1 day) @ Artesunate 4 mg/kg body weight daily for 3 days plus Sulfadoxine (25 mg/kg body weight) and Pyrimethamine (1.25 mg/kg body weight) on day 1. This is to be accompanied by single dose of Primaquine (0.75 mg/kg body weight) preferably on day 2. However, considering the reports of resistance to partner drug SP In North-Eastern States, the Technical Advisory Committee has recommended to use the co-formulated tablet of Artemether-Lumefantrine (ACT-AL) in North-Eastern States (Not recommended during the first trimester of pregnancy and in children weighing <5 kg).

For details of treatment of uncomplicated and complicated malaria in certain endemic areas, special population groups (pregnancy, children etc.) All healthcare providers should also follow the NVBDCP National Guidelines for treatment of malaria (available at: https://nvbdcp.gov.in/WriteReadData/1892s/20627628441542176662.pdf).

### 6.5 Management of Leptospirosis and COVID-19 co-infection

#### 6.5.1 Pathogenesis
Leptospirosis is primarily a contagious disease of animals, occasionally infects humans caused by pathogenic spirochete of the genus leptospira. Urinary shedding of organisms from infected animals (reservoir and carrier hosts like rodents, cattle, etc.) is the most important source of these bacterial pathogens. Contact with the organism via infected urine or urine-contaminated media results in human infection.

The most consistent pathologic finding in leptospirosis is vasculitis of capillaries, manifested by endothelial edema, necrosis, and lymphocytic infiltration. Capillary vasculitis is found in every affected organ system.

6.4.2 Diagnosis

The definitive diagnosis of leptospirosis depends on sero-conversion or four fold rise in antibody titer or isolation of leptospires from clinical specimen. Positive serology, preferably Microscopic Agglutination Test (MAT), using a range of Leptospira strains for antigens that should be representative of local strains.

a) Enzyme Linked Immuno Sorbent Assay (ELISA): ELISA is a sensitive and specific test for the immunological diagnosis of Leptospirosis. It is of particular value as a serological screening test because of its relative simplicity in comparison to the MAT (Microscopic Agglutination Test). ELISA test can also be used in epidemiological studies to determine the sero-incidence/sero-prevalence of Leptospirosis)

b) Rapid immunodiagnostics: Lepto dip-stick, Lepto lateral flow and Lepto Tek Dri Dot assays are based on IgM detection. These are screening tests and the results require confirmation by MAT.

Isolation (and typing) from blood or other clinical materials through culture of pathogenic leptospires. Culture and isolation can be very difficult requiring special media and longer incubation.

6.4.3 Clinical Features

Leptospirosis has a varied clinical manifestation. Like COVID, the severity of illness ranges from asymptomatic, mild self-limiting febrile illness to fulminant fatal disease. The disease typically presents as one of the following clinical categories.

(i) Mild influenza like illness

(ii) Weil’s syndrome characterized by jaundice, renal failure, haemorrhagic manifestations and myocarditis.

(iii) Meningitis/menigo-encephalitis

(iv) Pulmonary haemorrhage with respiratory failure

Clinical illness lasts for a few days to 3 weeks or longer. Generally, there are two phases in the illness. The early phase illness is characterized by abrupt onset of high fever, myalgia (calves and lumbar region) and headache (retro-orbital/frontal). Other early phase manifestations include nausea, vomiting, abdominal pain, diarrhoea, cough and conjunctival suffusion (a pathognomonic finding of leptospirosis). Late phase illness occurs, 4-9 days after onset of symptoms, and is characterized by prolonged fever and systemic complications such as jaundice, renal failure, bleeding, respiratory failure etc.
6.4.4 Specific therapeutic considerations

All clinically suspected leptospirosis patients in Leptospira endemic area during rainy season should be given presumptive treatment of leptospirosis i.e. Tab. Doxycycline 100 mg twice daily for 7 days.

Note: In children less than 6 years 30 to 50 mg/kg/day of Cap. Amoxycillin/Cap. Ampicillin should be given in divided doses 6 hourly for 7 days.

Diagnosis and clinical management of leptospirosis in community setting should be in accordance with national guidelines for prevention and control of leptospirosis (available at: https://www.ncdc.gov.in/linkimages/Leptospirosis1232331086.pdf)

6.6 Management of Scrub Typhus and COVID-19 co-infection

6.6.1 Pathogenesis

Scrub typhus is transmitted by the mite Leptotrombidium deliense. The vector mites inhabit sharply demarcated areas in the soil where the microecosystem is favourable (mite islands). Human beings are infected when they trespass into these mite islands and are bitten by the mite larvae (chiggers).

Scrub Typhus causes perivasculitis of the small blood vessels. O tsutsugamushi stimulates phagocytosis by the immune cells, and then escapes the phagosome. Scrub typhus may disseminate into multiple organs through endothelial cells and macrophages, resulting in the development of fatal complications.

6.6.2 Diagnosis

Scrub typhus may be diagnosed in the laboratory by: (i) isolation of the organism (ii) serology (iii) molecular diagnosis (PCR).

Several serological tests are currently available for the diagnosis of rickettsial diseases like Weil-Felix Test (WFT), Indirect Immuno-flourescence (IIF), Enzyme linked Immunosorbent assay (ELISA) etc. Although many techniques have been used successfully for rickettsial sero diagnosis, relatively few are used regularly by most laboratories. BSL-3 Lab is not required for performing serological tests.

Enzyme linked Immunosorobent Assay (ELISA): ELISA techniques, particularly immunoglobulin M (IgM) capture assays, are probably the most sensitive tests available for rickettsial diagnosis, and the presence of IgM antibodies, indicate recent infection with rickettsial diseases. In cases of infection with O. tsutsugamushi, a significant IgM antibody titer is observed at the end of the first week, whereas IgG antibodies appear at the end of the second week.

Molecular diagnosis (PCR) - For PCR, blood sample is collected in tubes containing EDTA or sodium citrate. However, blood clot, whole blood or serum can also be used for the detection of O. tsutsugamushi, R. rickettsii, R. typhi and R. prowazekii organisms by PCR test.

6.6.3 Clinical Features
Patients with scrub typhus may present early or later in the course of their disease. Inoculation through the chigger bite is often painless and unnoticed. A small painless papule initially appears at the site of infection and enlarges gradually. An area of central necrosis develops and is followed by eschar formation. The eschar (if present) is well developed at the initiation of the fevers, which may drive the patient to seek medical attention.

The incubation period lasts 6-20 days (average, 10 days). After incubation, persons may experience headaches, shaking chills, lymphadenopathy, conjunctival infection, fever, anorexia, and general apathy. The fever usually reaches 40-40.5°C (104-105°F).

6.6.4 Specific therapeutic considerations

If scrub typhus is suspected with COVID, treatment with Doxycycline (@ 200 mg/day in two divided doses for duration of 7 days) or Azithromycin (@ 500 mg in a single oral dose for 5 days) should be administered.

Management of the individual complications should be done as per the existing practices.

7. Early warning signs

If the patient is in a primary care setup, the following criteria should be monitored to assess patients clinical progress. Early warning signs for referral to higher centre are:

- Altered Mental Status (AVPU)
- Systolic blood pressure: <90mmHg or <20% of baseline in hypertensive patients
- Heart Rate/ Pulse Rate: <50 or >120 bpm
- SpO₂: <94 % on room air
- Respiratory Rate: <10 or >30 bpm
- Temperature: persistently >38°C
- Urine Output: <0.5 ml/Kg/Hr for consecutive 2 hrs
- Spontaneous bleeding/ haematuria
- Platelet count <50,000/cumm

8. Prevention

Even though the basic preventive strategies of COVID-19 and seasonal influenza are different from diseases discussed in this document, it is desirable that there is synergy in the prevention of these diseases. The States must make use of their resources effectively as staff is also diverted to provide COVID-19 response. This can be achieved by combining prevention activities.

7.1 Integrated surveillance: It must be ensured that IDSP networks are strengthened to include surveillance of COVID-19 cases besides dengue, malaria, chikungunya, leptospirosis, scrub typhus, seasonal influenza to maximize the use of resources.

7.2 Basic preventive measures for COVID-19 and seasonal influenza, like avoiding large gatherings, maintaining physical distance, hand hygiene and cough etiquette must be ensured at all times.

7.3 Vector control: Source reduction of mosquito breeding sites and adult control measures should be implemented in areas affected by or at risk of these diseases, especially in and around treatment facilities.
7.4 **Use of approved insect repellents** and ITN/LLINs is effective against vector borne diseases including scrub typhus.

7.5 **Preventive measures** against leptospirosis include wearing protective clothing for people at occupational risk (sanitation workers, rice-paddy and sugarcane workers etc.) and avoidance of swimming in water that may be contaminated.

7.4 **Vaccination** for seasonal influenza for healthcare workers and other high-risk groups to be implemented aggressively.

9. **Community involvement**

Community support must be garnered and community awareness drives on COVID-19 and other seasonal diseases must be ensured.

10. **Conclusion**

A concerted effort is required in prevention, surveillance, behaviour change communication and management of such cases. Alert vigil, a high index of suspicion and constant awareness of the possibility of co-infections can help physicians avert the adverse outcome of cases with coinfection and improve clinical outcomes.
The following table shows salient features of certain common infections

<table>
<thead>
<tr>
<th>Onset</th>
<th>COVID 19</th>
<th>Dengue</th>
<th>Malaria</th>
<th>Chikungunya</th>
<th>Leptospirosis</th>
<th>Seasonal Influenza</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>IP: 2-14 days.</td>
<td>IP: ranges from 3-14 days</td>
<td>P. Falciparum (IP: 9-14 days)</td>
<td>IP: 1-12 days</td>
<td>IP: 2-26 days</td>
<td>IP: 1-4 days</td>
</tr>
<tr>
<td>(onset of symptom</td>
<td>(onset of symptom</td>
<td></td>
<td>P. vivax (IP 10-14 days). Acute onset of high-grade intermittent fever</td>
<td>(Onset of symptom average 3-7 days)</td>
<td>(onset of symptom Average- 6-10 days)</td>
<td>(onset of symptom average - 2 days)</td>
</tr>
<tr>
<td>average 5-7 days)</td>
<td>average 4-7 days)</td>
<td></td>
<td>Acute onset of high-grade intermittent fever</td>
<td>(onset of symptom average 4-7 days)</td>
<td>Acute onset of moderate to high grade continuous fever</td>
<td>Acute onset of moderate to high grade continuous fever</td>
</tr>
<tr>
<td>Acute onset of low to moderate grade continuous fever</td>
<td>Acute onset of high-grade continuous fever</td>
<td>Fever, chills, malaise, fatigue, diaphoresis (sweating), headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhoea, arthralgias, and myalgias</td>
<td>Fever, rigors, myalgia, headache, Conjunctival suffusion, nausea, vomiting, and diarrhoea</td>
<td>Fever, cough, sore throat, and nasal discharge, headache, myalgia and malaise,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td>Cough</td>
<td>Fever, Headache, Nausea Vomiting retro-orbital pain myalgia arthralgia rash bleeding</td>
<td>Fever Rash Malaise Arthralgia Myalgia Red Eyes</td>
<td>Fever, rigors, myalgia, headache, Conjunctival suffusion, nausea, vomiting, and diarrhoea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>staple on symptom</td>
<td>Dyspnocia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>Myalgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>Sore throat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Abdominal pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhinorrhoea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signs</td>
<td>Tachypnea, Decreased oxygen saturation, Multi organ involvement</td>
<td>Signs of hypotension and shock, hemorrhagic manifestations (petechiae), positive tourniquet test</td>
<td>Pallor Palpable spleen</td>
<td>Swelling and tenderness of joints, Subconjunctival Haemorrhages, Red eyes, Muscle tenderness, Splenomegaly, Hepatomegaly, Muscle rigidity Skin rash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warning signs</td>
<td>Respiratory distress</td>
<td>Persistent vomiting, Abdominal tenderness, Fluid Accumulation, Persistent high grade intermittent fever, vomiting, lethargy, low urine</td>
<td>High grade fever, progressive increase of myalgia and arthralgia.</td>
<td>High grade fever, LFT derangement,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SpO₂&lt;94 %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Annexure**
<table>
<thead>
<tr>
<th>Complications</th>
<th>Mucosal Bleed</th>
<th>output</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARDS</td>
<td>Hypotensive Shock, bleeding, Organ involvement, Metabolic derangement.</td>
<td>Altered Sensorium, Acidosis, ARDS Renal Impairment Liver Dysfunction</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td></td>
<td>respiratory failure, cardiovascular decompensation, myocarditis, acute hepatitis, renal</td>
</tr>
<tr>
<td>Acute Cardiac Injury</td>
<td></td>
<td>failure, hemorrhage, Meningoencephalitis</td>
</tr>
<tr>
<td>Shock</td>
<td></td>
<td>Acute Flaccid Paralysis</td>
</tr>
<tr>
<td>Pulmonary Embolism</td>
<td></td>
<td>GBS</td>
</tr>
<tr>
<td>Shock</td>
<td></td>
<td>Aseptic Meningitis</td>
</tr>
<tr>
<td>Acute Stroke</td>
<td></td>
<td>Jaundice and renal failure (Weil’s Disease)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pulmonary hemorrhage, acute respiratory distress syndrome (ARDS), uveitis, optic neuritis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>peripheral neuropathy, myocarditis, and rhabdomyolysis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ARDS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myositis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rhabdomyolisis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acute MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myocarditis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pericarditis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Encephalitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myelitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GBS</td>
</tr>
</tbody>
</table>

IP = Incubation period